AGAida Guseykhanovna Gadzhigoroeva

Aida Guseykhanovna Gadzhigoroeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aida Guseykhanovna Gadzhigoroeva has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hair loss during treatment of obesity: current state of the problem and potential solutions

    by E. A. Troshina, L. A. Suplotova, F. Kh. Dzgoeva, L. A. Ruyatkina, A. G. Gadzhigoroeva, O. A. Gromova, Yu. Yu. Romanova

    Obesity and overweight are significant medical and social problems, and current approaches to their treatment, including hypocaloric diets, bariatric interventions, and pharmacotherapy, including incretin drugs (e.g., glucagon-like peptide-1 receptor agonists), can be accompanied by the development of diffuse hair loss. This article, prepared following a discussion at an expert council, systematizes current data on the prevalence and clinical and morphological variants of alopecia associated with weight loss. The main pathogenic mechanisms are discussed, including metabolic stress, protein-energy malnutrition, and micronutrient deficiencies. Special attention is paid to the role of biotin and vitamin D in maintaining hair follicle function, as well as to risk groups for alopecia in patients undergoing treatment for obesity. Approaches to the prevention, monitoring, and comprehensive management of such patients are presented, taking into account the need to maintain adherence to the main therapy. This article systematizes current data on the prevalence and clinical and morphological variants of alopecia associated with weight loss. It examines the main pathogenic mechanisms, including metabolic stress, protein-energy malnutrition, and micronutrient deficiencies. Special attention is paid to the role of biotin and vitamin D in maintaining hair follicle function, as well as to risk groups for alopecia in patients undergoing treatment for obesity. Approaches to prevention, monitoring, and comprehensive management of these patients are presented, taking into account the need to maintain adherence to the primary therapy.

  • Clinical and Immunological Phenotypes of Alopecia Areata in Children with Concomitant Atopic Dermatitis: Results of a Cluster Analysis

    by N.N. Potekayev, G.P. Tereshchenko, A.G. Gadzhigoroeva, A.L. Savastenko, M. Kurdi, O.V. Zhukova

    Background. Alopecia areata (AA) and atopic dermatitis (AD) are chronic immune-mediated diseases that frequently coexist in children. Despite established epidemiological links, the internal structure of this comorbidity, including how objective disease severity and polyatopy correlate, remains poorly characterized. Aim. To identify and characterize clinical-immunological phenotypes of AA in children with concomitant AD using cluster analysis. Methods. A single-center, cross-sectional study included 68 children aged 5—16 years with AA and AD. Assessments included disease severity (SALT, SCORAD), age of AA onset, serum total IgE, quality of life (CDLQI), and atopic comorbidity (Atopy Index: 0=AD only, 1=+1 atopic condition, 2=+≥2 conditions). Spearman’s correlation and k-means clustering (variables: SALT, SCORAD, IgE, age of AA onset) were used. Results. Correlation analysis revealed a moderate positive association between AA and AD severity (ρ=+0.512, p<0.001). Earlier AA onset correlated significantly with more severe hair loss (ρ=–0.418, p=0.001). Cluster analysis identified three distinct phenotypes: (1) «Early-Onset, Severe AA» (n=22): Early onset (3.0 years), universal hair loss (SALT 100.0%), high CDLQI (11.0); (2) «Late-Onset, Mild Disease» (n=25): Later onset (8.0 years), mild AA (SALT 18.8%) and AD (SCORAD 22.6), lowest IgE (87.6 IU/mL); (3) «Severe Atopic» (n=21): Extreme atopy with highest IgE (847.0 IU/mL), severe AD (SCORAD 52.7) and AA (SALT 77.5%). A higher Atopy Index was associated with increased AD severity (p=0.003) and IgE levels (p=0.015). Conclusion. This study reveals significant heterogeneity in pediatric AA with AD, delineating distinct phenotypic profiles. The findings suggest at least two pathways to severe alopecia: one driven by very early disease onset and another by a severe, systemic Th2 atopic burden. Stratification by age of onset, disease severity, and atopic load facilitates personalized management and identifies children at the highest risk for severe disease and quality of life impairment.

  • Alopecia areata morbidity structure considering the association with atopic dermatitis in the population of Moscow in comparison with data from the federal register

    by G.P. Tereshchenko, A.G. Gadzhigoroeva, O.V. Zhukova, O.L. Novozhilova, E.V. Tolstoguzova, E.M. Berezovskaya, D.YU. Vurdov, E.P. Piterskaya, I.YU. Golousenko

    Background. Alopecia areata (AA) is an autoimmune disease in which association with atopic dermatitis (AD) is one of the prognostically adverse factors. The relevance of studying the structure of AA morbidity taking into account atopic comorbidity is caused by the lack of modern epidemiological data and age differences in clinical manifestations. Objective. To study the structure of AA morbidity in the population of Moscow and the federal register with emphasis on association with AD. Material and methods. A multicenter retrospective cohort study was carried out on the basis of data from the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology (MSPCDC) and the register of adult patients with AA for 2020—2024. The analysis included stratification according to ICD-10 (L63.0—L63.8), age groups (children aged 0—17 years and adults aged 18 years and older), assessment of association with AD (L20.8), calculation of extensive and intensive indicators (per 100 000 population). Methods of descriptive and analytical statistics were used: logistic regression, χ² and Mann—Whitney U tests, Bonferroni correction. Results. Prevalence of local forms (L63.8—84.9%) with a steady increase in their proportion (+3.2 p.p., p<0.001) especially among children (+8.6 p.p.) was revealed. Severe forms (L63.0—L63.2) amounted to 15.1%, more frequently occurring in children (15.2% versus 12.6%, p<0.05), especially ophiasis (1.7 times more frequent, p=0.013). Association with AD was noted in 2.7% of patients with maximum increase in children (+2.2 p.p., p=0.013). For comorbidity with AD, alopecia totalis (18.2% versus 8.1% in the overall group, OR 2.47, p<0.001) and universalis (7.4% versus 3.0%, OR 2.41, p=0.003) predominated. In the register (n=403), AD was diagnosed in 15.9% of patients predominantly with alopecia universalis (27.9%, OR 4.2, p<0.001). Conclusion. The significant association of severe forms of AA with AD emphasizes the importance of considering the atopic background in assessing the clinical course of alopecia.

  • Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study

    by N. N. Potekaev, A. G. Gadzhigoroeva, G. P. Tereshchenko, El Hawi Chaza, O. V. Zhukova

    Introduction . Tofacitinib and baricitinib are key systemic therapies for alopecia areata. However, direct comparative data on their efficacy and predictors of treatment response in real-world practice are limited. Aim . To compare the efficacy of tofacitinib and baricitinib in alopecia areata and identify predictors of treatment response. Materials and methods . A 52-week prospective comparative non-randomized cohort study included 45 patients with alopecia areata (SALT >25%). Patients were divided into two groups: tofacitinib (n = 18,10 mg daily) and baricitinib (n = 27,4 mg daily). Efficacy was assessed using SALT score dynamics, SALT30 (≥30% reduction), and SALT ≤20% (clinically significant outcome). Multiple regression models and Cox regression were used to identify predictors. Results . Groups differed in age and sex (p < 0.05). At week 52, the median hair regrowth was 81.4% for tofacitinib and 100.0% for baricitinib (p = 0.280). Achievement of SALT30 and SALT ≤20% was comparable (p > 0.05). Multivariate analysis identified baseline disease severity (SALT) as the only independent predictor of poorer response (β = -2.6% per 10% SALT, p = 0.047; OR for SALT ≤20% = 0.78, p = 0.038). Drug choice was not associated with efficacy. However, the proportion of early responders (SALT30 by week 12) was significantly higher with baricitinib (51.9% vs. 22.2%, p = 0.041). No serious adverse events occurred. Conclusions . Tofacitinib and baricitinib demonstrate comparable efficacy and a favorable safety profile in alopecia areata. Baricitinib is associated with a higher rate of early responders. The key predictor of response is the baseline extent of hair loss, which must be considered when planning therapy and evaluating outcomes.

  • Analysis of the use of GEBD in a group of patients with psoriasis (according to the data from the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Healthcare Department)

    by N.N. Potekaev, O.V. Zhukova, O.V. Dolya, A.G. Gadzhigoroeva, O.L. Novozhilova, S.I. Artemyeva, I.A. Mikhaylova, V.A. Volnukhin

    Psoriasis and psoriatic arthritis are chronic immune-mediated diseases with a high risk of comorbid conditions, for which the use of genetically engineered biological drugs (GEBD) is the most effective modern approach. Choice of the optimal drug requires considering clinical and demographic factors, treatment line and presence of concomitant diseases. Material and methods. A retrospective analysis of data from 405 patients (268 men, 137 women; mean age 46.7 years) with psoriasis vulgaris (43%) and arthropathic psoriasis (57%) who were receiving GEBD was performed. The distribution by drugs, frequency of efficacy «escape», influence of therapy line and comorbid pathology was evaluated. Statistical processing included the calculation of relative values, medians, interquartile range and correlation analysis. Results. Netakimab was the most frequently prescribed agent (45.4%) with a minimum frequency of therapy «escape» effect equal 12.8%. Among the used classes of drugs, inhibitors of IL-23 (10.3%) and IL-17 (25.3%) had the most stable positive effect; at the same time, TNF-α inhibitors showed the highest frequency of loss of effect (54.9%). The first line of therapy had a median response of 93.0%, which decreased by 2—6 p.p. to the 3rd—4th lines. Metabolic syndrome (40.1%) and cardiovascular diseases (32.1%) were associated with lower response to therapy, especially in application of TNF inhibitors. The IL-17 and IL-23 inhibitors showed stable efficacy even in late administration and in patients with comorbid pathology. Discussion. The obtained results confirm the need for a personalized selection of GEBD considering the diagnosis, line of therapy and profile of comorbid pathology. Drug classes of IL-23 and IL-17 inhibitors are preferred in late lines and in patients with high cardiometabolic risk. Conclusion. The implementation of a stratified approach to the choice of GEBD and early selection of the most effective drug can reduce the risk of «escape» effect and improve long-term treatment results.

  • Open Access

    A case of medulloblastoma and disseminated basal cell carcinoma of the skin in an 11‑year‑old female patient

    by T. S. Belysheva, V. V. Semenova, E. V. Sharapova, E. V. Krivova, E. E. Zelenova, A. G. Gadzhigoroeva, T. T. Valiev, T. V. Nasedkina

    Gorlin‑Goltz syndrome (GGS) is a rare autosomal dominant disorder caused by mutations in the PTCH1 and SUFU genes, key components of the Sonic Hedgehog signaling pathway. GGS is characterized by a high risk of developing tumors, primarily basal cell carcinoma (BCC) and medulloblastoma. The article presents a clinical case of an 11‑year‑old patient with PTCH1‑associated GGS, who was diagnosed with medulloblastoma at the age of 3 years, and by the age of 6 years, multiple basal cell skin cancer manifested. The clinical case highlights the importance of early diagnosis, timely molecular genetic testing and interdisciplinary monitoring to improve the prognosis and quality of life of patients with this syndrome.

  • Open Access

    Epidemiology of alopecia areata and its association with atopic dermatitis: A comparative analysis of data from the Moscow Center of Dermatovenereology and Cosmetology and the Federal Registry

    by A. G. Gadzhigoroeva, N. N. Potekaev, G. P. Tereshchenko, O. V. Zhukova, O. L. Novozhilova, E. V. Tolstoguzova, E. M. Berezovskaya, D. Yu. Vurdov, E. P. Piterskaya

    Introduction. One of the frequent comorbid conditions in alopecia areata is atopic dermatitis. Existing epidemiological data on alopecia areata and its association with atopic dermatitis remain contradictory and insufficiently studied, which underscores the relevance of this research.Aim. To study the epidemiological characteristics of alopecia areata in Moscow and its association with atopic dermatitis based on population and registry data.Materials and methods. A multicenter retrospective cohort study was conducted by analyzing medical records of patients diagnosed with alopecia areata and atopic dermatitis monitored at the Moscow Center for Dermatovenereology and Cosmetology from 2020 to 2024. Federal statistics (Form No. 12), outpatient records (No. 025/u-04), and a specialized alopecia areata registry were used. Rates per 100 000 population were calculated.Results. Significant differences in alopecia areata epidemiology were found (p < 0.001): prevalence in children (36.8/100 000) was 2.7 times higher than in adults (13.7/100 000), incidence – 22.2 vs. 7.9/100 000/year. Overall morbidity increased by +83.3%, prevalence by +62.6% (p < 0.001). The association between alopecia areata and atopic dermatitis was significant (p < 0.001): overall frequency 2.66% (95% CI: 2.37–2.95), higher in children (4.09%; OR = 8.3, 95% CI: 7.1–9.7) than adults (1.85%; OR = 14.1, 95% CI: 11.9–16.7). The highest increase occurred in 2021. In the adult alopecia areata registry, atopic dermatitis was present in 15.9% (64/403).Conclusions. The significant age-dependent association between alopecia areata and atopic dermatitis confirms atopic dermatitis as an established risk factor. Registry data provide more accurate information on comorbidities. The results justify screening for atopy in alopecia areata patients and the need for a multidisciplinary management approach.


  • Open Access

    Comparative evaluation of cytokine profiles in pediatric alopecia areata patients considering concomitant atopic diseases: An observational cohort cross-sectional study

    by N. N. Potekaev, G. P. Tereshchenko, O. V. Zhukova, A. G. Gadzhigoroeva, R. A. Khanferyan

    Background. Alopecia areata is an autoimmune disease affecting hair follicles that is frequently associated with atopic diseases. Studies on cytokine profiles in the context of atopic comorbidities help to identify the key immune mechanisms and specific immunophenotypes. The present study aims to identify immune differences in alopecia areata depending on the atopic status.Objective. To assess the serum levels of the main proinflammatory and regulatory cytokines in patients with alopecia areata, taking the presence of atopic diseases and the severity of the process into account.Methods. An observational cohort cross-sectional study was conducted at the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow City Health Department. The study included 44 alopecia areata patients aged 5–17 years, who were divided into two groups: 1) patients without atopy (n = 17); 2) patients with concomitant atopic diseases (n = 27). The severity of alopecia areata was graded using the Severity of Alopecia Tool (SALT). Cytokine concentration was studied via a multiplex assay (Luminex 200, ProcartaPlex Human Cytokine&Chemokine Panel 1A, 34plex). Of the 34 target parameters, granulocyte-macrophage colony-stimulating factor, interleukin-1β, and interleukin-15 were excluded from analysis due to the lack of detection in ≥20 participants. The remaining 31 parameters were compared between the groups and with the comparable healthy control group (n = 30). The correlation between the serum cytokine levels and alopecia severity was analyzed. The obtained data were statistically processed using Statistica 10.0 (StatSoft, USA) and Microsoft Excel 2016 (Microsoft Corporation, USA). The statistical significance level is α = 0.05. In order to estimate the correlation coefficient (r) and its statistical significance (p), Spearman’s coefficient was used. SCImagoGraphica software (SCImago LAB, Spain) was used for the graphic representation of the obtained results.Results. Differences between Groups 1–2 and the control group were found for 18 cytokines. Group 2 patients (with atopy) exhibited differences from the control group (p < 0.005) in the distribution of levels of all Type 2 cytokines, Type 1 cytokines (interleukin-2, interleukin-12, and tumor necrosis factor alpha and beta), and T helper 17 cytokines (interleukins 21, 22, 23, and 27), except for interleukin-17A. In Group 1 (without atopy), interleukin-4, interleukin-9, and eotaxin levels did not differ from those in the control group, while the level of interleukin-17A was elevated (p = 0.007). A direct comparison of the distribution of cytokine levels showed no statistically significant differences between Groups 1 and 2 in any of the parameters. The correlation between cytokine levels in alopecia areata patients and the disease severity was analyzed in all patients without dividing them according to their atopic status due to the limited sample size in the subgroups. The levels of interleukins 1 alpha, 10, 21, 22, 23, 27 and tumor necrosis factor beta were positively correlated with alopecia severity, especially interleukin-23 (r = 0.372, p = 0.008); a negative correlation with SALT scores was observed for interleukin-2 (r = −0.457, p = 0.011) and interleukin-4 (r = −0.489, p = 0.006).Conclusion. The obtained results confirm the complex and systemic nature of immune abnormalities in alopecia areata. T helper 2 cytokines are clearly involved in the pathophysiologic process, with comorbid atopic diseases enhancing the T helper 2 response, potentially modulating interleukin-17A expression. The severe course of alopecia is associated with the activation of T helper 17 mediators (except for interleukin-17A) and a decrease in the levels of interleukins 2 and 4. The obtained data justify the appropriateness of personalized therapy that takes the atopic status and cytokine profile into account.


  • Open Access

    Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

    by Nekma Meah, Jane Li, Dmitri Wall, Katherine York, Bevin Bhoyrul, Laita Bokhari, Lachlan Coulthard, Leila Asfour, Leonardo Spagnol Abraham, Daniel Asz‐Sigall, et al.

    Background: As the incidence of frontal fibrosing alopecia (FFA) continues to rise, there is a need for an optimal treatment algorithm for FFA. Objectives: To produce an international consensus statement on the treatment modalities and prognostic indicators of FFA. Methods: Sixty‐nine hair experts from six continents were invited to participate in a three‐round Delphi process. The final stage was held as a virtual meeting facilitated via Zoom. The consensus threshold was set at ≥66%. Results: Of 365 questions, expert consensus was achieved in 204 (56%) questions following completion of the three rounds. Three additional questions were included at the final meeting. The category with the strongest consensus agreement was disease monitoring (9; 100%). Questions pertaining to physical therapies achieved the least category consensus (15; 40%), followed by systemic therapy (45; 43%). Limitations: The study lacked sufficient representation from Africa and South America. Conclusions: SOFFIA highlights areas of agreement and disagreement among experts. Robust research is warranted to provide evidence‐based treatment recommendations.


  • A clinical case of familial alopecia areata in combination with immune pathology

    by N.N. Potekaev, O.V. Zhukova, A.G. Gadzhigoroeva, G.P. Tereshchenko, S.I. Artemyeva, I.A. Mikhaylova, M.A. Kochetkov, V.YU. Udzhukhu

    Alopecia areata (AA) is a chronic inflammatory disease that causes partial or complete hair loss and is based on autoimmune processes. Current studies are actively investigating the use of JAK inhibitors for AA treatment, but data on the safety and efficacy of these drugs in patients with congenital immunodeficiency are practically non-existent. A unique clinical case of familial form of severe AA in two sisters with congenital immune disorders, that caused certain difficulties in treatment, is presented. The older sister, 24 years old, has been diagnosed with primary immunodeficiency — selective IgA deficiency combined with IgG2 deficiency, and the younger sister, 18 years old, is under observation with suspicion of immunodeficiency with a predominant defect of antibodies. Both patients receive targeted therapy with tofacitinib, in presence of which a partial hair regeneration, more pronounced in the younger sister, has been noted. This clinical case emphasizes the need for multidisciplinary interaction of dermatologists, immunologists and geneticists in treating patients with AA and congenital immune disorders. Special attention should be paid to clinical and laboratory monitoring to minimize the risk of infections associated with therapy using JAK inhibitors. Our observation contributes to the understanding of genetic and immune mechanisms of AA and confirms the possibility of JAK inhibitors application in patients with autoimmune diseases affected by immunodeficiency. These data may serve as an addition to the development of new recommendations and treatment algorithms in such cases, and still the final efficacy and safety of such therapy require further study.